No Data
No Data
Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Market Cap Dropped CN¥1.2b Last Week; Retail Investors Bore the Brunt
Huahai Pharmaceutical's Unit Gets Registration Nod for Levetiracetam Oral Solution
Zhejiang Huahai Pharmaceutical (600521.SH): Registration certificate obtained for pharmaceutical oral solution of levetiracetam.
On July 19, Gelun Hui reported that its subsidiary, Changxing Pharmaceutical Co., Ltd., received the Drug Registration Certificate issued by the National Medical Products Administration (NMPA) for oral solution of Levetiracetam. The oral solution is mainly used as an adjunctive treatment for partial seizures in adult, pediatric and infants over one month old with epilepsy.
Huahai Pharmaceutical Gets Nod to Register Quetiapine Fumarate Tablets
Zhejiang Huahai Pharmaceutical Subsidiaries Get Regulatory Nod for Tumor Clinical Trial; Shares Down 3%
Zhejiang Huahai Pharmaceutical (600521.SH): HB0046 injection received drug clinical trial approval.
Zhejiang Huahai Pharmaceutical (600521.SH) announced that its subsidiary, Shanghai Huaotai Biomedical Pharmaceutical Co., Ltd. and Huabo Biomedical Pharmaceutical Technology (Shanghai) Co., Ltd., have received the Approval Notice for Drug Clinical Trial of HB0046 Injection issued by the National Medical Products Administration. Recently, the National Medical Products Administration has approved the clinical trial of the drug for late-stage solid tumors.
No Data